Evidence map›Paper›PMID 36412685›Full record

Trial reportTomography (Ann Arbor, Mich.)2022

[

Cristina Ferrari, Paolo Mammucci, Valentina Lavelli, Antonio Rosario Pisani, Anna Giulia Nappi, Dino Rubini, Angela Sardaro, Giuseppe Rubini

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Tomography (Ann Arbor, Mich.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Role ofMolecular imaging and radionuclide therapy · 2024
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Cristina FerrariInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0002-0168-8551
Paolo MammucciInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Valentina LavelliInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0002-7603-1706
Antonio Rosario PisaniInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Anna Giulia NappiInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0002-9046-6378
Dino RubiniInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0003-3807-0752
Angela SardaroSection of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Giuseppe RubiniInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.ORCID 0000-0003-1972-3308
University of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, there is still no consensus on the most accurate PET radiopharmaceutical to early detect prostate cancer (PCa) relapse. A tailored radiotracer choice based on a specific patient's profile could ensure prompt disease detection and an improvement in patients management. We aimed to compare the [

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overCarboxylic AcidsCholineCyclobutanesEarly Detection of CancerHumansMaleMiddle AgedNeoplasm Recurrence, LocalOrganic ChemicalsProstate-Specific AntigenCarboxylic AcidsCholineCyclobutanesfluciclovine F-18fluorocholinefluoromethylcholineOrganic ChemicalsProstate-Specific Antigen[18F]fluciclovine[18F]fluorocholinebiochemical recurrencePET/CTprostate cancerPSA

Identifiers

PMID36412685
PMCPMC9680271
OpenAlexW4308475480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.